<DOC>
	<DOCNO>NCT00593944</DOCNO>
	<brief_summary>The purpose study see dose MDX-1342 , monoclonal antibody , safe tolerable patient chronic lymphocytic leukemia ( CLL ) . Information responses patient may drug also collect .</brief_summary>
	<brief_title>Study MDX-1342 Patients With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Chronic lymphocytic leukemia ( CLL ) monoclonal hematopoietic disorder characterize progressive expansion lymphocytes B-cell lineage . These small , mature-appearing lymphocyte accumulate blood , bone marrow , lymph node , spleen . CLL common leukemia wester world account 25 % 30 % adult leukemia . CD19 , integral membrane protein , express pro-B cell function co-stimulatory molecule regulate mature B-cell activation enhance B-cell proliferation . MDX-1342 , fully human monoclonal antibody , demonstrate specifically bind human CD19 antigen high affinity . Therefore , theorize MDX-1342 block activation B cell stimulation , decrease number cancerous B cell clone .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>relapsed/refractory CD19positive CLL At least 28 day since prior treatment CLL ECOG PS 02 Screening laboratory value must meet No prior antiCD19 antibody tx No active , uncontrolled infection No prior allogeneic bone marrow transplant No autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>CLL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>B cell</keyword>
	<keyword>leukemia</keyword>
	<keyword>lymphocyte</keyword>
	<keyword>antibody</keyword>
	<keyword>monoclonal</keyword>
	<keyword>cancer</keyword>
	<keyword>blood</keyword>
</DOC>